Back to results

TerminatedPhase 2

Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease

NCT02322021

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

Bellflower, California, United States

+20 additional locations

View on ClinicalTrials.gov

Save this trial

Quick facts

Start date: 2014-11-26
Enrollment: 70 participants
Sponsor: Eisai Inc.
Purpose: treatment

Locations (21)

Bellflower, California, United States
Costa Mesa, California, United States
Glendale, California, United States
Irvine, California, United States
Aventura, Florida, United States
Boca Raton, Florida, United States
Brooksville, Florida, United States
Lake Worth, Florida, United States
Orlando, Florida, United States
Port Charlotte, Florida, United States
Atlanta, Georgia, United States
Savannah, Georgia, United States
Wichita, Kansas, United States
Kalamazoo, Michigan, United States
Mount Arlington, New Jersey, United States
Scotch Plains, New Jersey, United States
Charlotte, North Carolina, United States
Dayton, Ohio, United States
Port Royal, South Carolina, United States
Dallas, Texas, United States
San Antonio, Texas, United States

Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease — TrialFind